Epstein Secrets

ng "big game" • Short time & limited capital to profit/liquidity • I have hands-on experience doing this successfully • Competitive fees - 2%/20% Target >25% ROI for the portfolio. 3x return in 5 years, 5x return in 7 years DACART CAPITAL LLC EFTA_R1_01138845 EFTA02295571 Return on Investment X

and ViroPharma Incorporated. DACART CAPITAL LLC EFTA_R1_01138848 EFTA02295574 References • Michael Eisenson - Charlesbank, Managing Partner • Alan Salzman - VantagePoint, Managing Partner ■ Kevin Hrusovsky - Perkin Elmer, President of Life Sciences & Technology ■ Dan Junius - lmmunogen, CEO • Al Sommers - JHU, For

ng "big game" • Short time & limited capital to profit/liquidity • I have hands-on experience doing this successfully • Competitive fees — 2%/20% Target >25% ROI for the portfolio. 3x return in 5 years, 5x return in 7 years DACARI CAPI I AL LL, EFTA00506150 Return on Investment Xenogen Jan-98

Pharmaceuticals and ViroPharma Incorporated. DACAR 1 CAPIIAL LLC EFTA00506153 References • Michael Eisenson - Charlesbank, Managing Partner • Alan Salzman - VantagePoint, Managing Partner • Kevin Hrusovsky - Perkin Elmer, President of Life Sciences & Technology • Dan Junius - Immunogen, CEO • Al Sommers - JHU, For

ng "big game" • Short time & limited capital to profit/liquidity • I have hands-on experience doing this successfully • Competitive fees — 2%/20% Target >25% ROI for the portfolio. 3x return in 5 years, 5x return in 7 years DACARI CAPI I AL LL, EFTA00506197 Advisory Board Thomas Shenk, • Dr. S

% returns over the course of four years. DACAR T C. API IAL LIS.; EFTA00506200 References • Michael Eisenson - Charlesbank, Managing Partner • Alan Salzman - VantagePoint, Managing Partner • Alex Barkas - Prospect, Managing Partner • Kevin Hrusovsky - Caliper Life Sciences, CEO • Dan Junius - lmmunogen, CEO • Al So